DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia

BACKGROUND: Despite its inconsistent response rate, decitabine, a demethylating agent, is often used as a non-intensive alternative therapeutic agent for acute myeloid leukemia (AML). It has been reported that relapsed/refractory AML patients with t(8;21) translocation achieved better clinical outco...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Shujiao, Li, Yan, Shi, Xuanren, Wang, Lei, Cai, Diya, Zhou, Jingfeng, Yu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983225/
https://www.ncbi.nlm.nih.gov/pubmed/36864492
http://dx.doi.org/10.1186/s13148-023-01458-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983225/
https://www.ncbi.nlm.nih.gov/pubmed/36864492
http://dx.doi.org/10.1186/s13148-023-01458-0

Ejemplares similares